Lassa fever - the road ahead.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
accepted:
05
08
2022
pubmed:
14
9
2022
medline:
20
1
2023
entrez:
13
9
2022
Statut:
ppublish
Résumé
Lassa virus (LASV) is endemic in the rodent populations of Sierra Leone, Nigeria and other countries in West Africa. Spillover to humans occurs frequently and results in Lassa fever, a viral haemorrhagic fever (VHF) associated with a high case fatality rate. Despite advances, fundamental gaps in knowledge of the immunology, epidemiology, ecology and pathogenesis of Lassa fever persist. More frequent outbreaks, the potential for further geographic expansion of Mastomys natalensis and other rodent reservoirs, the ease of procurement and possible use and weaponization of LASV, the frequent importation of LASV to North America and Europe, and the emergence of novel LASV strains in densely populated West Africa have driven new initiatives to develop countermeasures for LASV. Although promising candidates are being evaluated, as yet there are no approved vaccines or therapeutics for human use. This Review discusses the virology of LASV, the clinical course of Lassa fever and the progress towards developing medical countermeasures.
Identifiants
pubmed: 36097163
doi: 10.1038/s41579-022-00789-8
pii: 10.1038/s41579-022-00789-8
pmc: PMC9466315
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-96Subventions
Organisme : NIAID NIH HHS
ID : U01 AI151812
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI135995
Pays : United States
Informations de copyright
© 2022. Springer Nature Limited.
Références
Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738–750 (2015).
doi: 10.1016/j.cell.2015.07.020
Pinneo, L. & Pinneo, R. Mystery virus from Lassa. Am. J. Nurs. 71, 1352–1355 (1971).
Watts, G. M. Lily Lyman Pinneo. Lancet 380, 1552 (2013).
doi: 10.1016/S0140-6736(12)61871-6
Leifer, E., Gocke, D. J. & Bourne, H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am. J. Trop. Med. Hyg. 19, 677–679 (1970).
doi: 10.4269/ajtmh.1970.19.677
Buckley, S. M., Casals, J. & Downs, W. G. Isolation and antigenic characterization of Lassa virus. Nature 227, 174 (1970). This work reports the initial isolation and characterization of Lassa virus.
doi: 10.1038/227174a0
Buckley, S. M. & Casals, J. Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus. Am. J. Trop. Med. Hyg. 19, 680–691 (1970).
doi: 10.4269/ajtmh.1970.19.680
Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263–265 (1974). This work is the first demonstration that Lassa virus is rodent-borne.
doi: 10.1126/science.185.4147.263
Fichet-Calvet, E., Becker-Ziaja, B., Koivogui, L. & Gunther, S. Lassa serology in natural populations of rodents and horizontal transmission. Vector Borne Zoonotic Dis. 14, 665–674 (2014).
doi: 10.1089/vbz.2013.1484
Fichet-Calvet, E., Lecompte, E., Koivogui, L., Daffis, S. & ter Meulen, J. Reproductive characteristics of Mastomys natalensis and Lassa virus prevalence in Guinea, West Africa. Vector Borne Zoonotic Dis. 8, 41–48 (2008).
doi: 10.1089/vbz.2007.0118
Kakaī, C. G. et al. Improving cross-border preparedness and response: lessons learned from 3 lassa fever outbreaks across Benin, Nigeria, and Togo, 2017–2019. Health Secur. 18, S105–S112 (2020).
doi: 10.1089/hs.2019.0080
Patassi, A. A. et al. Emergence of lassa fever disease in northern Togo: report of two cases in Oti district in 2016. Case Rep. Infect. Dis. 2017, 8242313 (2017).
Sogoba, N., Feldmann, H. & Safronetz, D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health 59, 43–47 (2012).
doi: 10.1111/j.1863-2378.2012.01469.x
Jahrling, P. B. et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141, 580–589 (1980). This work presents the development of a non-human primate model.
doi: 10.1093/infdis/141.5.580
Peters, C. J. et al. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 134, 5–68 (1987).
Hartnett, J. N. et al. Current and emerging strategies for the diagnosis, prevention and treatment of Lassa fever. Future Virol. 10, 559–584 (2015).
doi: 10.2217/fvl.15.41
Goba, A. et al. An outbreak of Ebola virus disease in the Lassa fever zone. J. Infect. Dis. https://doi.org/10.1093/infdis/jiw239 (2016).
doi: 10.1093/infdis/jiw239
Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res. 133, 218–222 (2016). This work presents the initial characterization of Lassa virus monoclonal antibodies in animals.
doi: 10.1016/j.antiviral.2016.08.012
Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146–1149 (2017).
doi: 10.1038/nm.4396
Cashman, K. A. et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antivir. Res. 90, 70–79 (2011).
doi: 10.1016/j.antiviral.2011.02.012
Hansen, F., Jarvis, M. A., Feldmann, H. & Rosenke, K. Lassa virus treatment options. Microorganisms https://doi.org/10.3390/microorganisms9040772 (2021).
doi: 10.3390/microorganisms9040772
Salami, K., Gouglas, D., Schmaljohn, C., Saville, M. & Tornieporth, N. A review of Lassa fever vaccine candidates. Curr. Opin. Virol. 37, 105–111 (2019).
doi: 10.1016/j.coviro.2019.07.006
Gale, T. V., Horton, T. M., Hoffmann, A. R., Branco, L. M. & Garry, R. F. Host proteins identified in extracellular viral particles as targets for broad-spectrum antiviral inhibitors. J. Proteome Res. 18, 7–17 (2019).
Rowe, W. P. et al. Arenoviruses: proposed name for a newly defined virus group. J. Virol. 5, 651–652 (1970).
doi: 10.1128/jvi.5.5.651-652.1970
Oldstone, M. B. Arenaviruses. I. The epidemiology molecular and cell biology of arenaviruses. Introduction. Curr. Top. Microbiol. Immunol. 262, V–XII (2002).
Hastie, K. M., Kimberlin, C. R., Zandonatti, M. A., MacRae, I. J. & Saphire, E. O. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression. Proc. Natl Acad. Sci. USA 108, 2396–2401 (2011).
doi: 10.1073/pnas.1016404108
Hastie, K. M., King, L. B., Zandonatti, M. A. & Saphire, E. O. Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease. PloS ONE 7, e44211 (2012).
doi: 10.1371/journal.pone.0044211
Hastie, K. M. et al. Crystal structure of the Lassa virus nucleoprotein–RNA complex reveals a gating mechanism for RNA binding. Proc. Natl Acad. Sci. USA 108, 19365–19370 (2011).
doi: 10.1073/pnas.1108515108
Hastie, K. M. & Saphire, E. O. Lassa virus glycoprotein: stopping a moving target. Curr. Opin. Virol. https://doi.org/10.1016/j.coviro.2018.05.002 (2018).
doi: 10.1016/j.coviro.2018.05.002
Kouba, T. et al. Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity. Nat. Commun. 12, 7018 (2021).
doi: 10.1038/s41467-021-27305-5
Xu, X. et al. Cryo-EM structures of Lassa and Machupo virus polymerases complexed with cognate regulatory Z proteins identify targets for antivirals. Nat. Microbiol. 6, 921–931 (2021).
doi: 10.1038/s41564-021-00916-w
Hastie, K. M. et al. Crystal structure of the oligomeric form of Lassa virus matrix protein Z. J. Virol. 90, 4556–4562 (2016).
doi: 10.1128/JVI.02896-15
Joseph, S. & Campbell, K. P. Lassa fever virus binds matriglycan-A polymer of alternating xylose and glucuronate-on α-dystroglycan. Viruses https://doi.org/10.3390/v13091679 (2021).
doi: 10.3390/v13091679
Brouillette, R. B. et al. TIM-1 mediates dystroglycan-independent entry of Lassa virus. J. Virol. https://doi.org/10.1128/jvi.00093-18 (2018).
doi: 10.1128/jvi.00093-18
Fedeli, C., Moreno, H. & Kunz, S. The role of receptor tyrosine kinases in lassa virus cell entry. Viruses https://doi.org/10.3390/v12080857 (2020).
doi: 10.3390/v12080857
Fedeli, C. et al. Axl can serve as entry factor for Lassa virus depending on the functional glycosylation of dystroglycan. J. Virol. https://doi.org/10.1128/jvi.01613-17 (2018).
doi: 10.1128/jvi.01613-17
Goncalves, A. R. et al. Role of DC-SIGN in Lassa virus entry into human dendritic cells. J. Virol. 87, 11504–11515 (2013).
doi: 10.1128/JVI.01893-13
Cao, W. et al. Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282, 2079–2081 (1998).
doi: 10.1126/science.282.5396.2079
Li, S. et al. Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike. PloS Pathog. 12, e1005418 (2016).
doi: 10.1371/journal.ppat.1005418
Israeli, H., Cohen-Dvashi, H., Shulman, A., Shimon, A. & Diskin, R. Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses. PloS Pathog. 13, e1006337 (2017).
doi: 10.1371/journal.ppat.1006337
Radoshitzky, S. R., Buchmeier, M. J. & de la Torre, J. C. in Field’s Virology 7th edn Vol. 1 Ch. 18 (eds Howley, P. M. & Knipe, D. M.) (Lippincott Williams & Wilkins, 2020).
Auperin, D. D., Sasso, D. R. & McCormick, J. B. Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology 154, 155–167 (1986).
doi: 10.1016/0042-6822(86)90438-1
Reguera, J. et al. Comparative structural and functional analysis of Bunyavirus and Arenavirus cap-snatching endonucleases. PloS Pathog. 12, e1005636 (2016).
doi: 10.1371/journal.ppat.1005636
Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923–928 (2017). This work reveals the structure of the native trimeric structure of the Lassa virus glycoprotein.
doi: 10.1126/science.aam7260
Lenz, O., ter Meulen, J., Klenk, H. D., Seidah, N. G. & Garten, W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl Acad. Sci. USA 98, 12701–12705 (2001).
doi: 10.1073/pnas.221447598
Yasuda, S. U. & Jiro Molecular mechanism of arenavirus assembly and budding. Viruses 4, 2049–2079 (2012).
doi: 10.3390/v4102049
Ehichioya, D. U. et al. Phylogeography of Lassa virus in Nigeria. J. Virol. https://doi.org/10.1128/jvi.00929-19 (2019).
doi: 10.1128/jvi.00929-19
Bowen, M. D. et al. Genetic diversity among Lassa virus strains. J. Virol. 74, 6992–7004 (2000). This work examines Lassa virus phylogeny.
doi: 10.1128/JVI.74.15.6992-7004.2000
Mofolorunsho, K. C. Outbreak of lassa fever in Nigeria: measures for prevention and control. Pan Afr. Med. J. 23, 210 (2016).
doi: 10.11604/pamj.2016.23.210.8923
Akhiwu, H. O. et al. Lassa fever outbreak in adolescents in north central Nigeria: report of cases. J. Virus Erad. 4, 225–227 (2018).
doi: 10.1016/S2055-6640(20)30306-X
Akpede, G. O., Asogun, D. A., Okogbenin, S. A. & Okokhere, P. O. Lassa fever outbreaks in Nigeria. Expert Rev. Anti Infect. Ther. 16, 663–666 (2018).
doi: 10.1080/14787210.2018.1512856
Ilori, E. A. et al. Epidemiologic and clinical features of Lassa fever outbreak in Nigeria, January 1–May 6, 2018. Emerg. Infect. Dis. 25, 1066–1074 (2019).
doi: 10.3201/eid2506.181035
Maxmen, A. Deadly Lassa-fever outbreak tests Nigeria’s revamped health agency. Nature 555, 421–422 (2018).
doi: 10.1038/d41586-018-03171-y
Siddle, K. J. et al. Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018. N. Engl. J. Med. 379, 1745–1753 (2018).
doi: 10.1056/NEJMoa1804498
Manning, J. T., Forrester, N. & Paessler, S. Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage. Front. Microbiol. 6, 1037 (2015).
doi: 10.3389/fmicb.2015.01037
Whitmer, S. L. M. et al. New lineage of Lassa virus, Togo, 2016. Emerg. Infect. Dis. 24, 599–602 (2018).
doi: 10.3201/eid2403.171905
Boisen, M. L. et al. Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. Viral Immunol. 28, 19–31 (2015).
doi: 10.1089/vim.2014.0108
Richmond, J. K. & Baglole, D. J. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 327, 1271–1275 (2003).
doi: 10.1136/bmj.327.7426.1271
Macher, A. M. & Wolfe, M. S. Historical Lassa fever reports and 30-year clinical update. Emerg. Infect. Dis. 12, 835–837 (2006).
doi: 10.3201/eid1205.050052
Wolf, T., Ellwanger, R., Goetsch, U., Wetzstein, N. & Gottschalk, R. Fifty years of imported Lassa fever–a systematic review of primary and secondary cases. J. Travel Med. https://doi.org/10.1093/jtm/taaa035 (2020).
doi: 10.1093/jtm/taaa035
Ehlkes, L. et al. Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. Eur. Surveill. https://doi.org/10.2807/1560-7917.Es.2017.22.39.16-00728 (2017).
doi: 10.2807/1560-7917.Es.2017.22.39.16-00728
Njuguna, C. et al. A challenging response to a Lassa fever outbreak in a non endemic area of Sierra Leone in 2019 with export of cases to The Netherlands. Int. J. Infect. Dis. 117, 295–301 (2022).
doi: 10.1016/j.ijid.2022.02.020
WHO. Lassa fever–United Kingdom of Great Britain and Northern Ireland. World Health Organization https://www.who.int/emergencies/disease-outbreak-news/item/lassa-fever-united-kingdom-of-great-britain-and-northern-ireland (2022).
Grange, Z. L. et al. Ranking the risk of animal-to-human spillover for newly discovered viruses. Proc. Natl Acad. Sci. USA 118, e2002324118 (2021).
doi: 10.1073/pnas.2002324118
Smither, A. R. & Bell-Kareem, A. R. Ecology of Lassa virus. Curr. Top. Microbiol. Immunol. https://doi.org/10.1007/82_2020_231 (2021).
doi: 10.1007/82_2020_231
Shaffer, J. G. et al. Lassa fever in post-conflict Sierra Leone. PloS Negl. Trop. Dis. 8, e2748 (2014).
doi: 10.1371/journal.pntd.0002748
Bonwitt, J. et al. At home with Mastomys and Rattus: human–rodent interactions and potential for primary transmission of Lassa virus in domestic spaces. Am. J. Trop. Med. Hyg. 96, 935–943 (2017).
Bonwitt, J. et al. Rat-atouille: a mixed method study to characterize rodent hunting and consumption in the context of Lassa fever. EcoHealth 13, 234–247 (2016).
doi: 10.1007/s10393-016-1098-8
Mari Saez, A. et al. Rodent control to fight Lassa fever: evaluation and lessons learned from a 4-year study in Upper Guinea. PloS Negl. Trop. Dis. 12, e0006829 (2018).
doi: 10.1371/journal.pntd.0006829
WHO. Lassa fever. World Health Organization https://www.who.int/health-topics/lassa-fever#tab=tab_1 (2022).
Knobloch, J. et al. Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol. 31, 389–398 (1980).
McCormick, J. B. & Fisher-Hoch, S. P. Lassa fever. Curr. Top. Microbiol. Immunol. 262, 75–109 (2002).
Akhuemokhan, O. C. et al. Prevalence of Lassa virus disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area. PloS Negl. Trop. Dis. 11, e0005711 (2017).
doi: 10.1371/journal.pntd.0005711
Okokhere, P. et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect. Dis. 18, 684–695 (2018).
doi: 10.1016/S1473-3099(18)30121-X
Ehichioya, D. U. et al. Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005–2008. Trop. Med. Int. Health 17, 1001–1004 (2012).
doi: 10.1111/j.1365-3156.2012.03010.x
Buba, M. I. et al. Mortality among confirmed lassa fever cases during the 2015–2016 outbreak in Nigeria. Am. J. Public Health 108, 262–264 (2018).
doi: 10.2105/AJPH.2017.304186
Branco, L. M. et al. Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report. Virol. J. 8, 404 (2011).
doi: 10.1186/1743-422X-8-404
Okogbenin, S. et al. Retrospective cohort study of Lassa fever in pregnancy, southern Nigeria. Emerg. Infect. Dis. https://doi.org/10.3201/eid2508.181299 (2019).
doi: 10.3201/eid2508.181299
Ilori, E. A. et al. Increase in Lassa fever cases in Nigeria, January–March 2018. Emerg. Infect. Dis. 25, 1026–1027 (2019).
doi: 10.3201/eid2505.181247
Ficenec, S. C. et al. Lassa fever induced hearing loss: the neglected disability of hemorrhagic fever. Int. J. Infect. Dis. 100, 82–87 (2020).
doi: 10.1016/j.ijid.2020.08.021
Ficenec, S. C., Schieffelin, J. S. & Emmett, S. D. A review of hearing loss associated with Zika, Ebola, and Lassa fever. Am. J. Trop. Med. Hyg. 101, 484–490 (2019).
doi: 10.4269/ajtmh.18-0934
Duvignaud, A. et al. Delayed-onset paraparesis in Lassa fever: a case report. Int. J. Infect. Dis. 92, 49–52 (2020).
doi: 10.1016/j.ijid.2019.12.022
Ezeomah, C. et al. Sequelae of Lassa fever: postviral cerebellar ataxia. Open Forum Infect. Dis. 6, ofz512 (2019).
doi: 10.1093/ofid/ofz512
Li, A. L. et al. Ophthalmic manifestations and vision impairment in Lassa fever survivors. PloS ONE 15, e0243766 (2020).
doi: 10.1371/journal.pone.0243766
Garry, R. F. Ebola virus can lie low and reactivate after years in human survivors. Nature 597, 478–480 (2021).
doi: 10.1038/d41586-021-02378-w
Lee, H. & Nishiura, H. Recrudescence of Ebola virus disease outbreak in West Africa, 2014–2016. Int. J. Infect. Dis. 64, 90–92 (2017).
doi: 10.1016/j.ijid.2017.09.013
McCormick, J. B. et al. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314, 20–26 (1986). This work reports a treatment study with ribavirin in humans.
doi: 10.1056/NEJM198601023140104
Eberhardt, K. A. et al. Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis. Int. J. Infect. Dis. https://doi.org/10.1016/j.ijid.2019.07.015 (2019).
doi: 10.1016/j.ijid.2019.07.015
Salam, A. P. et al. Time to reconsider the role of ribavirin in Lassa fever. PloS Negl. Trop. Dis. 15, e0009522 (2021).
doi: 10.1371/journal.pntd.0009522
Hastie, K. M., Bale, S., Kimberlin, C. R. & Saphire, E. O. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2, 151–156 (2012).
doi: 10.1016/j.coviro.2012.01.003
Huang, Q., Liu, X., Brisse, M., Ly, H. & Liang, Y. Effect of strain variations on Lassa virus Z protein-mediated human RIG-I inhibition. Viruses https://doi.org/10.3390/v12090907 (2020).
doi: 10.3390/v12090907
Watanabe, Y. et al. Structure of the Lassa virus glycan shield provides a model for immunological resistance. Proc. Natl Acad. Sci. USA 115, 7320–7325 (2018).
doi: 10.1073/pnas.1803990115
Branco, L. M. et al. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol. J. 8, 478 (2011).
doi: 10.1186/1743-422X-8-478
Prescott, J. B. et al. Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol. 17, 195–207 (2017).
doi: 10.1038/nri.2016.138
Sakabe, S. et al. Identification of common CD8
doi: 10.1128/jvi.00153-20
Sullivan, B. M. et al. High crossreactivity of human T cell responses between Lassa virus lineages. PloS Pathog. 16, e1008352 (2020).
doi: 10.1371/journal.ppat.1008352
Botten, J. et al. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. 80, 8351–8361 (2006).
doi: 10.1128/JVI.00896-06
Flatz, L. et al. T cell-dependence of Lassa fever pathogenesis. PloS Pathog. 6, e1000836 (2010).
doi: 10.1371/journal.ppat.1000836
Port, J. R. et al. Severe human Lassa fever is characterized by nonspecific T-cell activation and lymphocyte homing to inflamed tissues. J. Virol. https://doi.org/10.1128/jvi.01367-20 (2020).
doi: 10.1128/jvi.01367-20
Asogun, D. A. et al. Molecular diagnostics for lassa fever at Irrua Specialist Teaching Hospital, Nigeria: lessons learnt from two years of laboratory operation. PloS Negl. Trop. Dis. 6, e1839 (2012).
doi: 10.1371/journal.pntd.0001839
Boisen, M. L. et al. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci. Rep. 8, 5939 (2018).
doi: 10.1038/s41598-018-24246-w
Boisen, M. L. et al. Field evaluation of a pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak. Sci. Rep. 10, 8724 (2020).
doi: 10.1038/s41598-020-65736-0
Heinrich, M. L. et al. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Sci. Rep. 10, 16030 (2020).
doi: 10.1038/s41598-020-72539-w
Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 449–463 (2017).
doi: 10.2183/pjab.93.027
Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).
doi: 10.1038/srep14775
Oestereich, L. et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J. Infect. Dis. 213, 934–938 (2016).
doi: 10.1093/infdis/jiv522
Lingas, G., Rosenke, K., Safronetz, D. & Guedj, J. Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin. PloS Comput. Biol. 17, e1008535 (2021).
doi: 10.1371/journal.pcbi.1008535
Rosenke, K. et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg. Infect. Dis. 24, 1696–1699 (2018).
doi: 10.3201/eid2409.180233
Mendenhall, M. et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PloS Negl. Trop. Dis. 5, e1342 (2011).
doi: 10.1371/journal.pntd.0001342
Gowen, B. B. et al. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J. 7, 240 (2010).
doi: 10.1186/1743-422X-7-240
Raabe, V. N. et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin. Infect. Dis. 65, 855–859 (2017).
doi: 10.1093/cid/cix406
Larson, R. A. et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol. 82, 10768–10775 (2008).
doi: 10.1128/JVI.00941-08
Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).
doi: 10.1038/ncomms11544
Cross, R. W. et al. Antibody therapy for Lassa fever. Curr. Opin. Virol. 37, 97–104 (2019).
doi: 10.1016/j.coviro.2019.07.003
Hastie, K. M. et al. Convergent structures illuminate features for germline antibody binding and pan-Lassa virus neutralization. Cell 178, 1004–1015.e14 (2019).
doi: 10.1016/j.cell.2019.07.020
Buck, T. K. et al. Neutralizing antibodies against lassa virus lineage I. mBio https://doi.org/10.1128/mbio.01278-22 (2022).
doi: 10.1128/mbio.01278-22
White, J. M. et al. Drug combinations as a first line of defense against coronaviruses and other emerging viruses. mBio 12, e0334721 (2021).
doi: 10.1128/mbio.03347-21
Johnson, D. M., Cubitt, B., Pfeffer, T. L., de la Torre, J. C. & Lukashevich, I. S. Lassa virus vaccine candidate ML29 generates truncated viral RNAs which contribute to interfering activity and attenuation. Viruses https://doi.org/10.3390/v13020214 (2021).
doi: 10.3390/v13020214
Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccines Immunother. 13, 2902–2911 (2017).
doi: 10.1080/21645515.2017.1356500
Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539–551 (2020).
doi: 10.1172/JCI131958
Stein, D. R. et al. A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs. NPJ Vaccines 4, 8 (2019).
doi: 10.1038/s41541-019-0104-x
Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa–rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223 (2018).
doi: 10.1038/s41467-018-06741-w
Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl Med. https://doi.org/10.1126/scitranslmed.abf6348 (2021).
doi: 10.1126/scitranslmed.abf6348
Salvato, M. S. et al. A single dose of modified vaccinia ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge. Pathogens https://doi.org/10.3390/pathogens8030133 (2019).
doi: 10.3390/pathogens8030133
Wang, M. et al. Construction and immunological evaluation of an adenoviral vector-based vaccine candidate for Lassa fever. Viruses https://doi.org/10.3390/v13030484 (2021).
doi: 10.3390/v13030484
Fischer, R. J. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines 6, 32 (2021).
doi: 10.1038/s41541-021-00291-x
Müller, H. et al. Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. NPJ Vaccines 5, 71 (2020).
doi: 10.1038/s41541-020-00219-x
Branco, L. M. et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol. J. 7, 279 (2010).
doi: 10.1186/1743-422X-7-279
Kainulainen, M. H. et al. Protection from lethal Lassa disease can be achieved both before and after virus exposure by administration of single-cycle replicating Lassa virus replicon particles. J. Infect. Dis. 220, 1281–1289 (2019).
doi: 10.1093/infdis/jiz284
Gouglas, D., Christodoulou, M., Plotkin, S. A. & Hatchett, R. CEPI: driving progress toward epidemic preparedness and response. Epidemiol. Rev. 41, 28–33 (2019).
doi: 10.1093/epirev/mxz012
Koch, M. R. et al. Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone. PloS Negl. Trop. Dis. 15, e0009576 (2021).
doi: 10.1371/journal.pntd.0009576
Meyer, B. & Ly, H. Inhibition of innate immune responses is key to pathogenesis by arenaviruses. J. Virol. 90, 3810–3818 (2016).
doi: 10.1128/JVI.03049-15